Investigational Drug Information for RPT193
✉ Email this page to a colleague
What is the drug development status for RPT193?
RPT193 is an investigational drug.
There have been 4 clinical trials for RPT193.
The most recent clinical trial was a Phase 1 trial, which was initiated on May 1st 2022.
The most common disease conditions in clinical trials are Dermatitis, Atopic, Dermatitis, and Eczema. The leading clinical trial sponsors are RAPT Therapeutics, Inc. and [disabled in preview].
There is one US patent protecting this investigational drug and thirteen international patents.
Summary for RPT193
| US Patents | 1 |
| International Patents | 13 |
| US Patent Applications | 7 |
| WIPO Patent Applications | 1 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2022-05-01) |
| Vendors | 13 |
Recent Clinical Trials for RPT193
| Title | Sponsor | Phase |
|---|---|---|
| Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma | RAPT Therapeutics, Inc. | Phase 2 |
| Study of RPT193 in Healthy Adult Male Subjects | RAPT Therapeutics, Inc. | Phase 1 |
| An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis | RAPT Therapeutics, Inc. | Phase 2 |
Clinical Trial Summary for RPT193
Top disease conditions for RPT193
Top clinical trial sponsors for RPT193
International Patents for RPT193
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| RPT193 | Australia | AU2019212478 | 2038-01-26 | ⤷ Sign Up |
| RPT193 | Brazil | BR112020015056 | 2038-01-26 | ⤷ Sign Up |
| RPT193 | Canada | CA3089380 | 2038-01-26 | ⤷ Sign Up |
| RPT193 | China | CN111971279 | 2038-01-26 | ⤷ Sign Up |
| RPT193 | European Patent Office | EP3743418 | 2038-01-26 | ⤷ Sign Up |
| RPT193 | Israel | IL276295 | 2038-01-26 | ⤷ Sign Up |
| RPT193 | Japan | JP2021512152 | 2038-01-26 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
